Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hai DO

Physician Assistant Phoenix, AZ Physician Assistant

NPI 1245408764 CMS profile 11204610

3805 E Bell Rd, Ste 3100, Phoenix, AZ 85032

Open in the dashboard

General payments

$11,935

523 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hai DO of Phoenix, AZ is reported in the CMS Open Payments database as having received $11,935 across 523 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,810 128
2024 General $3,364 154
2023 General $3,755 143
2022 General $929 53
2021 General $1,076 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hai DO
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Hai DO were reported at $2,810. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Hai DO Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,076 $132 $37–$438 $132
2022 $929 $155 $48–$522 $149
2023 $3,755 $167 $52–$557 $160
2024 $3,364 $178 $55–$600 $164
2025 $2,810 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $2,185 51 payments
  2. ITI, Inc. $1,808 122 payments
  3. Otsuka America Pharmaceutical, Inc. $1,088 45 payments
  4. Teva Pharmaceuticals USA, Inc. $861 39 payments
  5. AbbVie, Inc. $615 41 payments
  6. Novo Nordisk Inc $515 30 payments
  7. Janssen Pharmaceuticals, Inc $437 17 payments
  8. UCB, Inc. $419 26 payments
  9. Lilly USA, LLC $397 15 payments
  10. Vanda Pharmaceuticals Inc. $393 15 payments
  11. Other $3,218 122 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,712 519 payments
  2. Education $223 4 payments
Products named General payments · program years 2021–2025
  1. INGREZZA $2,078 50 payments
  2. CAPLYTA Psychiatry $1,240 85 payments
  3. REXULTI $786 30 payments
  4. ABILIFY ASIMTUFII $573 22 payments
  5. CAPLYTA Psychiatry $568 37 payments
  6. UZEDY $506 17 payments
  7. RYBELSUS $494 29 payments
  8. Ozempic $396 28 payments
  9. Fintepla $393 25 payments
  10. FANAPT $393 15 payments
  11. Other $6,608 285 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

6,789

Median for Physician Assistant: 241

Drug cost

$813,175

Median for Physician Assistant: $4,110

Branded share of claims

21.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 66 $95,532
Vraylar Cariprazine Hcl Brand 63 $91,911
Rybelsus Semaglutide Brand 63 $86,066
Caplyta Lumateperone Tosylate Brand 39 $68,088
Abilify Maintena Aripiprazole Brand 26 $59,927
Invega Sustenna Paliperidone Palmitate Brand 12 $38,529
Januvia Sitagliptin Phosphate Brand 35 $35,411
Jardiance Empagliflozin Brand 38 $34,092
Eliquis Apixaban Brand 30 $29,538
Aristada Aripiprazole Lauroxil Brand 18 $28,345

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$665 39 —
INGREZZA
$478 — —
UZEDY
$301 — —
Austedo XR
$204 — —
FANAPT
$201 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

523 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record